ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia

AIMS: To assess long-term (78 weeks) alirocumab treatment in patients with heterozygous familial hypercholesterolaemia (HeFH) and inadequate LDL-C control on maximally tolerated lipid-lowering therapy (LLT). METHODS AND RESULTS: In two randomized, double-blind studies (ODYSSEY FH I, n = 486; FH II,...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Eur Heart J
Main Authors: Kastelein, John J.P., Ginsberg, Henry N., Langslet, Gisle, Hovingh, G. Kees, Ceska, Richard, Dufour, Robert, Blom, Dirk, Civeira, Fernando, Krempf, Michel, Lorenzato, Christelle, Zhao, Jian, Pordy, Robert, Baccara-Dinet, Marie T., Gipe, Daniel A., Geiger, Mary Jane, Farnier, Michel
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2015
Assuntos:
FASTTrack Esc Clinical Trial Update
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4644253/
https://ncbi.nlm.nih.gov/pubmed/26330422
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehv370
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares